medigraphic.com
Órgano oficial de la Sociedad Mexicana de Cirugía Dermatológica y Oncológica, AC

2016, Number 4

<< Back Next >>

Dermatología Cosmética, Médica y Quirúrgica 2016; 14 (4)

Cutaneous Cryptococcosis: A Review

Barbosa-Zamora A, de la Herrán-Millán P, BonifazA

Language: Spanish
References: 66
Page: 330-341
PDF size: 247.29 Kb.


ABSTRACT

Cutaneous cryptococcosis is a fungal infection caused by the encapsulated yeasts; Cryptococcus neoformans and Cryptococcus gattii. It can be classified in primary, causing most infections in immunocompetent patients and disseminated in immunocompromised mainly aids and post transplant patients. The clinical manifestations are very polymorphic. For diagnosis, it is necessary the isolation of Cryptococcus sp. in India ink, biopsy, dextrose agar culture and serologic tests targeting capsular antigens. Therapeutic management is divided in three stages: induction, consolidation and maintenance. Gold standard is Anfotericin b plus 5-fluorocitosine.


REFERENCES

  1. Chayakulkeeree M y Perfect JR. Cryptococcosis, Infect Dis Clin North Am 2006; 20: 507-44.

  2. Bonifaz A. Criptococosis, en Micología médica básica, 4a ed., México 2012; pp. 347-65.

  3. Gullo FP, Rossi SA, Sardi J de C et al. Cryptococcosis: epidemiology, fungal resistance, and new alternatives for treatment, Eur J Clin Microbiol Infect Dis 2013; 32: 1377-91.

  4. Moretti ML, Resende MR, Lazéra MS et al. Guidelines in cryptococcosis- 2008, Rev Soc Bras Med Trop 2008; 41: 524-44.

  5. Padilla MC, Alonzo L, Novales J et al. Criptococosis cutánea diseminada. Presentación de un caso, Rev Cent Dermatol Pascua 2004; 13: 17-20.

  6. May RC, Stone NR, Wiesner DL et al. Cryptococcus: from environmental saprophyte to global pathogen, Nat Rev Microbiol 2016; 14: 106-17.

  7. Kwon-Chung KJ, Fraser JA, Doering TL et al. Cryptococcus neoformans and Cryptococcus gattii, the etiologic agents of cryptococcosis, Cold Spring Harb Perspect Med 2014; 4: a019760.

  8. Srikanta D, Santiago-Tirado FH y Doering TL. Cryptococcus neoformans: historical curiosity to modern pathogen, Yeast 2014; 31: 47-60.

  9. Negroni R. Cryptococcosis, Clin Dermatol 2012; 30: 599-609.

  10. Arenas R. Criptococosis, en Micología médica Ilustrada, 5a ed., México 2014; 261-9.

  11. Centers for Disease Control and Prevention, Revised surveillance case definition for hiv infection United States, 2014, mmwr Recomm Rep 2014; 63: 1-10.

  12. Perfect JR. Cryptococcosis: a model for the understanding of infectious diseases, J Clin Invest 2014; 124: 1893-5.

  13. Lin X y Heitman J. The biology of the Cryptococcus neoformans species complex, Annu Rev Microbiol 2006; 60: 69-105.

  14. Morán MA, González GV, Espinoza JP et al. Criptococosis cerebral: análisis de 29 casos en 23 años de autopsias en el Hospital General de México, Rev Lat Patol 2008; 46: 222-7.

  15. Biancheri D, Kanitakis J, Bienvenu AL et al. Cutaneous cryptococcosis in solid organ transplant recipients. Epidemiological, clinical, diagnostic and therapeutic features, Eur J Dermatol 2012; 22: 651-7.

  16. Maziarz EK y Perfect JR. Cryptococcosis, Infect Dis Clin North Am 2016; 30: 179-206.

  17. Moreira TA, Ferreira MS, Ribas RM y Borges AS. Cryptococosis: clinical epidemiological laboratorial study and fungi varieties in 96 patients, Rev Soc Bras Med Trop 2006; 39: 255-8.

  18. Sharma D, Singh N, Kaushal S y Jain S. Isolated cutaneous cryptococcosis in clinically unsuspected idiopathic cd4 lymphocytopenia, J Cytol 2014; 31: 230-2.

  19. Liu Y, Qunpeng H, Shutian X y Honglang X. Fatal primary cutenous cryptococcosis: case report and review of published literature, Ir J Med Sci 2105; doi: 10.1007/s11845-015-1346-x.

  20. Syme RM, Bruno TF, Kozel TR y Mody CH. The capsule of Cryptococcus neoformans reduces T-lymphocyte proliferation by reducing phagocytosis, which can be restored with anticapsular antibody, Infect Immun 1999; 67: 4620-7.

  21. Lin X, Patel S, Litvintseva AP et al. Diploids in the Cryptococcus neoformans serotype A population homozygous for the alpha mating type originate via unisexual mating, PLoS Pathog 2009; 5: 1-18.

  22. Duncan C, Schwantje H, Stephen C et al. Cryptococcus gattii in wildlife of Vancouver Island, British Columbia, Canada, J Wildl Dis 2006; 42: 175-8.

  23. Olivares LR, Martínez KM, Cruz RM et al. Genotyping of Mexican Cryptococcus neoformans and C. gattii isolates by pcr-fingerprinting, Med Mycol 2009; 47: 713-21.

  24. Aye C, Henderson A, Yu H y Norton R. Cryptococcosis. The impact of delay to diagnosis, Clin Microbiol Infect 2016; doi: 10.1016/j. cmi.2016.04.022.

  25. Escandón P, Quintero E, Granados D et al. Isolation of Cryptococcus gattii serotype b from detritus of Eucalyptus trees in Colombia, Biomedica 2005; 25: 390-7.

  26. Hoang LM, Maguire JA, Doyle P et al. Cryptococcus neoformans infections at Vancouver Hospital and Health Sciences Centre (1997-2002): epidemiology, microbiology and histopathology, J Med Microbiol 2004; 53: 935-40.

  27. Castañón-Olivares LR. Complejo Cryptococcus neoformans-cryptococcus gattii, en Méndez-Tovar LJ, López-Martínez R y Hernández-Hernández F. Actualidades en micología médica, México, unam 2008; pp. 263-8.

  28. Steenbergen JN y Casadevall A. The origin and maintenance of virulence for the human pathogenic fungus Cryptococcus neoformans, Microbes Infect 2003; 5: 667-75.

  29. Guerrero A, Jain N, Goldman DL y Fries BC. Phenotypic switching in Cryptococcus neoformans, Microbiology 2006; 152: 3-9.

  30. Casadevall A, Steenbergen JN y Nosanchuk JD. Ready made virulence and dual use virulence factors in pathogenic environmental fungi the Cryptococcus neoformans paradigm, Curr Opin Microbiol 2003; 6: 332-7.

  31. Robertson EJ y Casadevall A. Antibody-mediated immobilization of Cryptococcus neoformans promotes biofilm formation, Appl Environ Microbiol 2009; 75: 2528-33.

  32. Jung WH y Kronstad JW. Iron and fungal pathogenesis: a case study with Cryptococcus neoformans, Cell Microbiol 2008; 10: 277-84.

  33. Pal P, Ray S, Patra SK y Mukherjee D. Disseminated cryptococcosis in an apparently immunocompetent patient presenting with primary intraventricular haemorrhage, bmj Case Rep 2015; doi: 10.1136/bcr- 2015-210250.

  34. Núñez M, Peacock JE Jr y Chin R Jr. Pulmonary cryptococcosis in the immunocompetent host. Therapy with oral fluconazole: a report of four cases and a review of the literature, Chest 2000; 118: 527-534.

  35. Rodríguez LF, Amann R, Verde E et al. Criptococosis diseminada en una paciente portadora de trasplante renal, Nefrol 2005; 25: 73-7.

  36. Du L, Yang Y, Gu K et al. Systemic review of published reports on primary cutaneous cryptococcosis in immunocompetent patients, Mycopathologia 2015; 180: 19-25.

  37. Wang J, Bartelt L, Yu D et al. Primary cutaneous cryptococcosis treated with debridement and fluconazole monotherapy in an immunosuppressed patient: a case report and review of the literature, Case Rep Infect Dis 2015; 2015: 131356.

  38. McKinney JL, Cerio D, Loghmanee C et al. Surgical management of primary cutaneous cryptococcosis after failed medical management, J Hand Microsurg 2015; 7: 116-8.

  39. Leao CA, Ferreira-Paim K, Andrade-Silva L et al. Primary cutaneous cryptococcosis caused by Cryptococcus gattii in a immunocompetent host, Med Mycol 2011; 49: 352-5.

  40. Nascimento E, Bonifácio da Silva ME, Martínez R y Von Zeska Kress MR. Primary cutaneous cryptococcosis in an immunocompetent patient due to Cryptococcus gattii molecular type vgi in Brazil: a case report and review of literature, Mycoses 2014; 57: 442-7.

  41. Lacaz Cda S, Heins-Vaccari EM, Hernández-Arriagada GL et al. Primary cutaneous cryptococcosis due to Cryptococcus neoformans var. gattii serotype b, in an immunocompetent patient, Rev Inst Med Trop Sao Paulo 2002; 44: 225-8.

  42. Leechawengwongs M, Milindankura S, Sahirapongsasuti K et al. Primary cutaneous cryptococcosis caused by Cryptococcus gatti vgii un a tsunami survivor from Thailand, Med Mycol Case Rep 2014; 6: 31-3.

  43. Neuville S, Dromer F, Morin O et al. Primary cutaneous cryptococcosis: a distinct clinical entity, Clin Infect Dis 2003; 36: 337-47.

  44. Severo LC, Zardo IB y Londero AT. Cutaneous cryptococcosis due to Cryptococcus neoformans var. gatti, Rev Iberoam Micol 2001; 18: 200-1.

  45. Jackson NA y Herring DB. Primary capsule-deficient cutaneous cryptococcosis in a sporotrichoid pattern in an immunocompetent host, Cutis 2015; 96: E26-9.

  46. Murad A y Murphy A. Primary cutaneous Cryptococcus neoformans serotype d presenting as painful ulcer and nodules on elbow of an immunocompetent patient, Ir J Med Sci 2014; 183: 691-2.

  47. Christianson J, Engber W y Andes D. Primary cutaneous cryptococcosis in immunocompetent and immunocompromised hosts, Med Mycol 2003; 41: 177-88.

  48. Ni W, Huang Q y Cui J. Disseminated cryptococcosis initially presenting as cellulitis in a patient suffering from nephrotic syndrome, bmc Nephrol 2013; 22: 14-20.

  49. Valente ES, Lazzarin MC, Koech BL et al. Disseminated cryptococcosis presenting as cutaneous cellulitis in an adolescent with systemic lupus erythematosus, Infec Dis Rep 2015; 3: 5743.

  50. Hall JC, Brewer JH, Crouch TT et al. Cryptococcal cellulitis with multiple sites of involvement, J Am Acad Dermatol 1987; 17: 329-32.

  51. Atarguine H, Hocar O, Abbad F y Rais H. Cutaneous cryptococcosis mimicking basal cell carcinoma and revealing systemic involvement in acquired immunodeficiency, J Mycol Med 2015; 25: 163-8.

  52. Kothiwala SK, Prajapat M y Kuldeep CM. Cryptococcal panniculitis in a renal transplant recipient: case report and review of literature, J Dermatol Case Rep 2015; 9: 76-80.

  53. Echaiz JF, Burnham CA y Bailey TC. A case of apophysomyces trapeziformis necrotizing soft tissue infection, Int J Infect Dis 2013; 17: 1240-2.

  54. Fernández-Flores A, Saeb-Lima M y Arenas-Guzmán R. Morphological findings of deep cutaneous fungal infections, Am J Dermatopathol 2014; 36: 531-3.

  55. Taneja J, Bhargava A, Loomba P et al. Cryptococcal granulomas in an immunocompromised hiv -negative patient, Indian J Pathol Microbiol 2008; 51: 553-5.

  56. Dinato SL, Dinato MM, Nakanishi CP et al. Disseminated cutaneous cryptococcosis in a patient with aids, Rev Inst Med Trop S Paulo 2006; 48: 353-8.

  57. Pan B, Chen M, Jia H et al. Multiple subcutaneous abscesses: a rare presentation of cutaneous cryptococcosis, Indian J Dermatol Venereol Leprol 2013; 79: 118-9.

  58. Lazzara M y Joshi A. Disseminated cryptococcosis involving the head and neck, bmj Case Rep 2014; doi:10.1136/bcr-2013-202306.

  59. Béogo R, Andonaba JB, Bamba S et al. Cryptococcosis: a ponttential aetiology of facial ulceration, J Micol Med 2014; 24: 185-8.

  60. Pappalardo MC y Melhem MS. Cryptococcosis: a review of the Brazilian experience for the disease, Rev Inst Med Trop Sao Paulo 2003; 45: 299-305.

  61. Gazzoni AF, Severo CB, Salles EF y Severo LC. Histopathology, serology and cultures in the diagnosis of cryptococcosis, Rev Inst Med Trop Sao Paulo 2009; 51: 255-9.

  62. Coelho C y Casadevall A. Cryptococcal therapies and drug targets: the old, the new and the promising, Cell Microbiol 2016; 18: 792-9.

  63. Liu PY, Yang Y y Shi ZY. Cryptococcal liver abscess: a case report of successful treatment with amphotericin-b and literature review, Jpn J Infect Dis 2009; 62: 59-60.

  64. Perfect JR, Dismukes WE, Dromer F et al. Clinical practice guidelines for the management of cryptococcal disease: 2010 update by the infectious diseases society of America, Clin Infec Dis 2010; 50: 291-322.

  65. Thompson GR, Wiederhold NP, Fothergill AW et al. Antifungal susceptibilities among different serotypes of Cryptococcus gattii and Cryptococcus neoformans, Antimicrob Agents Chemother 2009; 53: 309-11.

  66. Perfect JR y Bicanic T. Cryptococcosis diagnosis and treat




2020     |     www.medigraphic.com